Table 2.
Changes in studied parameters after sacubitril/valsartan treatment.
| Sacubitril/Valsartan | ||||
|---|---|---|---|---|
| Before | After | |||
| T-1 | T0 | T1 | p | |
| SAP (mmHg) | 122 ± 16 | 120 ± 15 | 116 ± 19 † | 0.037 |
| LVEDV (mL) | 193 ± 50 | 184 ± 57 | 173 ± 56 *† | <0.001 |
| LVESV (mL) | 136 ± 41 | 133 ± 48 | 116 ± 46 *† | <0.001 |
| LVEF (%) | 30 ± 6 | 29 ± 6 † | 34 ± 6 *† | <0.001 |
| MR (a.u.) | 1.8 ± 0.8 | 1.7 ± 0.8 | 1.6 ± 0.6 | 0.154 |
| LAV (mL) | 83 ± 29 | 82 ± 32 | 70 ± 27 *† | <0.001 |
| E/e’ | 10.8 ± 3.4 | 10.9 ± 3.4 | 9.7 ± 3.9 *† | 0.033 |
| TAPSE (mm) | 19.6 ± 3.8 | 19.8 ± 3.3 | 20.4 ± 3.4 | 0.281 |
| TR (a.u.) | 1.6 ± 0.7 | 1.5 ± 0.6 | 1.5 ± 0.6 | 0.541 |
| CVP (mmHg) | 4.9 ± 2.6 | 4.0 ± 2.2 | 4.4 ± 2.5 | 0.132 |
| PAPs (mmHg) | 32 ± 8 | 32 ± 7 | 30 ± 6 * | 0.049 |
| Creatinine (mg/dL) | 0.96 ± 0.24 | 0.99 ± 0.26 | 1.01 ± 0.22 | 0.404 |
| GFR-EPI (mL/min/1.73 m2) | 87 ± 20 | 84 ± 21 | 83 ± 20 | 0.268 |
| NTproBNP (pg/mL) | 857 ± 1105 | 1052 ± 1321 | 614 ± 653 *† | 0.017 |
| RRI (%) | 66.9 ± 5.5 | 67.0 ± 5.5 | 64.9 ± 5.5 *† | <0.001 |
Data expressed as mean ± standard deviation. p refers to linear fixed model. T-1 available in 49 patients. * p < 0.05 vs. T0; † p < 0.05 vs. T-1. CVP: central venous pressure; E/e’: the ratio between the peak of the E wave (E), through mitral pulsed Doppler at the level of the mitral leaflets, and early diastolic velocity peak (e’) at the level of the septal and lateral mitral annulus, through tissue Doppler imaging; GFR-EPI: estimated glomerular filtration rate by EPI formula; LAV: left atrial volume; LVEDV: left ventricular end-diastolic volume; LVEF: left ventricular ejection fraction; LVESV: left ventricular end-systolic volume; MR: mitral regurgitation; NT-proBNP: amino-terminal brain natriuretic peptide; PAPs: estimated systolic pulmonary arterial pressure; RRI: renal resistance index; SAP: systolic arterial pressure; TAPSE: peak of tricuspid annulus systolic excursion; TR: tricuspid regurgitation.